An Open-label, Multi-center, Dose Escalation Phase I Study of Single Agent RO5520985 (Vanucizumab), and in Combination With Atezolizumab, Administered as an Intravenous Infusion in Patients With Locally Advanced or Metastatic Solid Tumors
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Atezolizumab (Primary) ; Vanucizumab (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Roche
- 18 Apr 2018 Results from AURELIA and NCT01688206 studies, presented at the 109th Annual Meeting of the American Association for Cancer Research
- 03 Apr 2018 Status changed from active, no longer recruiting to completed.
- 28 Feb 2018 Planned End Date changed from 30 Nov 2020 to 1 Mar 2020.